Management of mastocytosis

Clinics in Dermatology

Volumn 21, Issue 4, 2003, Pages 274-277

  Almahroos, Mona ^a   Kurban, Amal K ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALIPHATIC AMINE; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; CIMETIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; CYPROHEPTADINE; DOXEPIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; KETOTIFEN; LANSOPRAZOLE; LORATADINE; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PEPTIDOLEUKOTRIENE; PIPERAZINE DERIVATIVE; PSORALEN; RANITIDINE; UNINDEXED DRUG;

ANAPHYLAXIS; CELL STIMULATION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; FLUSHING; HEADACHE; HUMAN; INCIDENCE; MAST CELL; MASTOCYTOSIS; ONSET AGE; PAIN; PATIENT CARE; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PUVA; REVIEW; SKIN DEFECT; SYMPTOM; TREATMENT INDICATION; URTICARIA; URTICARIA PIGMENTOSA;

EID: 0142156004     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(03)00043-9     Document Type: Article

References (40)

1. Pauls J.D., Brems J., Pockros P.J., et al. Mastocytosis diverse presentations and outcomes . Arch Intern Med. 159:1999;401-405.
2. Ispas L., Henriksen R.A., Metzger W.J. The many faces of systemic mastocytosis. Ann Allergy Asthma Immunol. 87:2001;6-14.
3. Katsamba A.D., Karpouzis A.J., Koumantaki-Mathioudaki E., et al. Mastocytosis with skin manifestations current status . J Eur Acad Dermatol Venereol. 13:1999;155-165.
4. Tharp M.D. Mastocytosis. Curr Probl Dermatol. 10:1998;175-210.
5. Weidner N., Austen K.F. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol. 96:1991;S26-31.
6. Akin C., Metcalfe D.D. Mastocytosis. Leung D.Y., Greeves M.W. Allergic skin disease: a multidisciplinary approach . 2000;337-352 Marcel Dekker, Inc, NewYork.
7. Hartmann K., Metcalfe D.D. Pediatric mastocytosis. Hematol Oncol Clin North Am. 14:2000;625-640.
8. Hartmann K., Henz B.M. Mastocytosis recent advances in defining the disease . Br J Dermatol. 144:2001;682-695.
9. Kettelhut B.V., Metcalfe D.D. Pediatric mastocytosis. J Invest Dermatol. 96:1991;S15-18.
10. Chang A., Tung R.C., Schlesinger T., et al. Familial cutaneous mastocytosis. Pediatr Dermatol. 18:2001;271-276.
11. Valent P., Horny H.-P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis a consensus proposal . Leuk Res. 25:2001;603-625.
12. Hartmann K., Henz B.M. Classification of cutaneous mastocytosis a modified consensus proposal . Leuk Res. 26:2002;483-484.
13. Soter N.A. The skin in mastocytosis. J Invest Dermatol. 96:1991;S32-39.
14. Bütner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis a possible explanation of divergent clinical behavior . J Invest Dermatol. 111:1998;1227-1231.
15. Li C.-Y. Diagnosis of mastocytosis value of cytochemistry and immunohistochemistry . Leuk Res. 25:2000;537-541.
16. Roberto L.J., Oates J.A. Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol. 96:1991;S19-25.
17. Metcalfe D.D. The treatment of mastocytosis an overview . J Invest Dermatol. 96:1991;S55-59.
18. Marone G., Spadaro G., Granata F., et al. Treatment of mastocytosis pharmacologic basis and current concepts . Leuk Res. 25:2001;583-594.
19. Stellato C., de Paulis A., Cirillo R., et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology. 74:1991;1078-1086.
20. Fricker M., Helbling A., Schwartz L., et al. Hymenoptera sting anaphylaxis and urticaria pigmentosa clinical findings and results of venom immunotherapy in ten patients . J Allergy Clin Immunol. 100:1997;11-15.
21. Oude Elberink J.N., de Monchy J.G., Kors J.W., et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allerg Clin Immunol. 99:1997;153-154.
22. Murphy M., Walsh D., Drumm B., et al. Bullous mastocytosis a fatal outcome . Pediatr Dermatol. 16:1999;452-455.
23. Worobec AS, Metcalfe DD. Systemic anaphylaxis. In: Fauci AS, Lichtenstein LB, editors. Current therapy in allergy, immunology and rheumatology. St Louis: Mosby-Year Book, 1996:170-7.
24. Kettelhut B.V., Metcalfe D.D. Pediatric mastocytosis. Ann Allergy. 73:1994;197-207.
25. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 14:2000;659-687.
26. Enomoto U., Kusakabe H., Matsumura T., et al. Diffuse cutaneous mastocytosis responding to cyproheptadine. Clin Exp Dermatol. 24:1999;16-18.
27. Kettelhut B.V., Berkebile C., Bradley D., et al. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol. 83:1989;866-870.
28. 1 receptor blocker cetirizine as compared to other second-generation antihistamines. Mol Pharmacol. 54:1998;113-121.
29. 2-antagonists a meta-analysis of their efficacy in treating bleeding peptic ulcer . Aliment Pharmacol Ther. 15:2001;917-926.
30. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 138:1998;489-495.
31. Kurosawa M., Amano H., Kanbe N., et al. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J Allergy Clin Immunol. 103:1999;S412-420.
32. Stege H., Schöpf E., Ruzicka T., et al. High-dose UVAI for urticaria pigmentosa (letter). Lancet. 347:1996;64.
33. Godt O., Proksch E., Streit V., et al. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology. 195:1997;35-39.
34. Worobec A.S., Metcalfe D.D. Mastocytosis current treatment concepts . Int Arch Allergy Immunol. 127:2002;153-155.
35. Bedlow A., Gharrie S., Harland C.C. The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd YAG laser . J Cutan Laser Ther. 2:2000;45-47.
36. Ellis D.L. Treatment of telangiectasia macularis eruptiva perstans with 585-nm flash-pumped dye laser. Dermatol Surg. 22:1996;33-37.
37. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744.
38. Wedi B., Kapp A. Pathophysiological role of leukotrienes in dermatological diseases potential therapeutic implications . Biodrugs. 15:2002;729-743.
39. Mellor E.A., Maekawa A., Austen K.F., et al. Cysteinyle leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA. 98:2001;7964-7969.
40. Mellor E.A., Austen K.F., Boyce J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med. 195:2002;583-592.